ISSN 2063-5346
For urgent queries please contact : +918130348310

To assess role of atropine 0.01% eye drops in myopia progression and its effect over ocular surface

Main Article Content

Dr. Sandeep Jain, Dr. Nida Khan
» doi: 10.48047/ecb/2023.12.Si6.040


Assessment of Eye drop Atropine 0.01 % in controlling myopia progression and its effect on ocular surface. Methods: The Prospective study was conducted on 50 participants aged 8-16 years with progressive myopia > 1D/year attending Outpatient department, Department of Ophthalmology, of a Multi-Speciality tertiary health care hospital & research centre. Participants received 0.01 % atropine eye drops once at night in both eyes. Myopic progression (MP), axial length (AL) elongation, ocular surface and any adverse reactions to atropine 0.01 % eye drops are recorded at baseline, 6 months and 1 year. Results: Out of 50 participants, 45 (90 eyes) completed study. After 1 year MP was only - 0.52 D (IQR 0.38-0.75), which was statistically significant than baseline MP of more than -1.0 D. Changes in MP, AL was statistically significant in all age groups, baseline MP and gender. No adverse events and no significant changes in ocular surface were noted. Out of 45 participants 6 were non responders (MP> - 0.75 D), other 39 participants were good responders (MP< -0.75 D). There is a moderate negative corelation of age with MP and AL (r= -0.43; r= -0.48 respectively). The children in the non-responder group were younger and having high baseline SE and baseline MP than the responder group, the data was statistically significant (p<0.001). Conclusion: The results of current study showed the effectiveness of 0.01% atropine in reducing MP and axial length in Central Indianeyes in 1 year.

Article Details